William Blair Brokers Lower Earnings Estimates for GPCR

Key Points

• William Blair downgraded its Q3 2025 earnings estimates for Structure Therapeutics, expecting a loss of ($0.36) per share, down from a previous estimate of ($0.27).
• The company reported ($0.36) earnings per share for the recent quarter, which was below the analysts' consensus estimate of ($0.28).
• Structure Therapeutics is currently rated as a "Buy" by eight investment analysts, with an average target price of $75.71, despite recent price target cuts from several firms.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Analysts at William Blair cut their Q3 2025 EPS estimates for Structure Therapeutics in a research report issued on Wednesday, August 6th. William Blair analyst A. Hsieh now anticipates that the company will post earnings of ($0.36) per share for the quarter, down from their prior estimate of ($0.27). The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. William Blair also issued estimates for Structure Therapeutics' Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.35) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.51) EPS and FY2027 earnings at ($1.51) EPS.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).

A number of other analysts have also commented on GPCR. HC Wainwright cut their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. JMP Securities cut their price objective on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. Citigroup started coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Guggenheim cut their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, June 23rd. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $75.71.

Structure Therapeutics Stock Down 2.3%

Shares of GPCR stock traded down $0.44 during trading on Monday, reaching $18.73. The company's stock had a trading volume of 161,190 shares, compared to its average volume of 876,008. The business has a fifty day moving average price of $19.58 and a 200-day moving average price of $21.65. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -17.78 and a beta of -1.89. Structure Therapeutics has a one year low of $13.22 and a one year high of $45.37.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of GPCR. GF Fund Management CO. LTD. bought a new stake in Structure Therapeutics during the fourth quarter worth about $34,000. National Bank of Canada FI raised its holdings in Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after buying an additional 2,766 shares during the last quarter. Assetmark Inc. raised its holdings in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after purchasing an additional 820 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in Structure Therapeutics by 25.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after purchasing an additional 455 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd raised its holdings in Structure Therapeutics by 310.7% during the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after purchasing an additional 3,213 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.